Poster and Platform Presentations by PDCMDC Members

Movement Disorder Society (MDS)
15th International Congress of Parkinson's Disease and Movement Disorders in Toronto, Canada (June 5-9, 2011)

• Deep brain stimulation: Hardware related complications in patients with movement disorders.
  

  Baizabal Carvallo JF, Mostile G, Almaguer M, Davidson A, Simpson R, Jankovic J

• The long-term impact of early versus delayed treatment with rotigotine transdermal system in patients with early-stage, idiopathic Parkinson's disease.
  

  Boroojerdi B, Watts RL, Jankovic J, Surmann E, Ghys L

• IncobotulinumtoxinA (NT-201) injections are safe and effective in adult subjects with blepharospasm across dosing intervals in a repeated dose-study.
  

  Brodsky M, Jankovic J, Evidente VGH, Fernandez HH, Grafe SK

• The prevalence of symptomatic orthostatic hypotension in patients with Parkinson's disease and atypical parkinsonism.
  

  Brown CH, Ha AD, York MK, Jankovic J

• Correlation of patient impression with the cervical dystonia impact questionnaire.
  

  Charles PD, Jankovic J, Stacy M, Adler CH, Comella C, Brin M, Bloudek LB, Varon SF, Schwartz M, Papapetropoulos S, CD PROBE Study Group

• Convergence spasm in conversion disorders: Prevalence in psychogenic and other movement disorders compared to controls.
  

  Fekete R, Baizabal-Carvallo JF, Ha AD, Jankovic J

• Constant current DBS: A randomized controlled clinical trial in Parkinson's disease: 12 month results.
  

  Gallo BV, Okun MS, Mandybur G, Arle J, Elias J, Ford B, Horn S, Hung S, Jankovic J, Junn FS, Marshall F, Stewart RM, Swope D, Verhagen L, Tagliati M

• Essential tremor quantification during activities of daily living.
  

  Heldman DA, Filipkowski D, Jankovic J, Vaillancourt D, Prodoehl J, Elble RJ, Giuffrida JP

• Identification of a novel downstream target of Nurr1 transcription factor for midbrain dopamine neuron development.
  

  Hen X, Li L, Zhang X, Jankovic J, Le W

• Cervical dystonia patient registry for observation of onabotulinumtoxinA efficacy (CD PROBE): Study design of a prospective observational registry.
  

  Jankovic J, Stacy M, Charles PD, Adler CH, Comella C, Brin M, Papapetropoulos S, CD PROBE Study Group

• Programming parameters and outcome in GPi deep brain stimulation (DBS) for Tourette syndrome (TS).
  

  Jimenez-Shahed J

• A mechanistic study of proteasome inhibition-induced iron misregulation in dopaminergic neuron degeneration.
  

  Li X, Xie W, Jankovic J, Le W

• Amplitude fluctuations in essential tremor. A prospective study.
  

  Mostile G, Fekete R, Giuffrida JP, Yaltho T, Davidson A, Nicoletti A, Zappia M, Jankovic J

• A randomized controlled trial of constant current DBS active stimulation versus off stimulation in Parkinson's disease.
  

  Okun MS, Gallo BV, Mandybur G, Arle J, Elias J, Ford B, Horn S, Humg S, Jankovic J, Junn F, Marshall F, Stewart RM, Swope D, Verhagen L, Tagliati M

• Lubiprostone for constipation in Parkinson's disease, a multicenter, placebo controlled parallel trial.
  

  Ondo WG, Daleiden A, Davidson A, Hunter C, Jahan I, Miller A, Sullivan K, Zesiewicz TA

• Efficacy and safety of IPX066, a new carbidopa-levodopa (CD-LD) extended-release formulation, in LD-naive early Parkinson's disease (APEX-PD trial).
  

  Pahwa R, Ellenbogen A, Jankovic J, Hauser R, Fahn S, Clinical Team at Impax Pharmaceuticals

• Patients' perspective of tetrabenazine two years after FDA approval.
  

  Palao AM, Hunter CB, Jankovic J

• Alpha-synuclein: Possible link between Parkinson's disease and melanoma.
  

  Pan T, Zhu J, Li X, Jankovic J

• Brain glucose hypometabolism in a subject carrying an unstable allele of intermediate CAG33 repeat length in the Huntington's disease gene.
  

  Squitieri F, Esmaeilzadeh M, Ciarmiello A, Jankovic J

• Postural instability and gait difficulty scores from the MDS-UPDRS.
  

  Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Tilley BC

• Assessing dissociative pathology in psychogenic movement disorders: Clinical utility of the Dissociative Experiences Scale-II.
  

  Strutt AM, Scott BM, Ferrara J, York MK, Jankovic J

• Safety data in a randomized controlled trial of constant current deep brain stimulation versus lead placement alone for treatment of motor fluctuations in Parkinson's disease.
  

  Tagliati M, Gallo BV, Mandybur G, Arle J, Elias J, Ford B, Horn S, Hung S, Jankovic J, Junn FS, Marshall F, Stewart RM, Swope D, Verhagen L, Okun MS

• Peripheral trauma and movement disorders: A systematic review of reported cases.
  

  van Rooijen DE, Geraedts EJ, Marinus J, Jankovic J, van Hilten JJ

American Academy of Neurology (AAN)
63rd Annual Meeting in Honolulu, Hawaii (April 9-16, 2011)

• Deep brain stimulation system revision, and hardware related complications in 512 patients with movement disorders.
  

  Baizabal Carvallo JF, Mostile G, Simpson R, Almaguer M, Davidson A, Jankovic J

• Cervical dystonia patient registry for observation of BOTOX® efficacy (CD PROBE): Interim results of pain-related outcomes.
  

  Charles P, Adler CH, Stacy M, Comella C, Jankovic J, Boo LM, Brin M, Papapetropoulos S

• Peer-to-peer clinical research outreach and education: A model for increasing clinical study awareness, inquiry and enrollment among people with Parkinson's.
  

  Elliott R, Todaro V, Cook M, Jimenez-Shahed J, Kavanagh P, Thomas CA, Welsh M, Zhang L

• Efficacy and safety of repeated incobotulinumtoxin A injections in subjects with cervical dystonia previously treated with botulinum toxin.
  

  Evidente VG, Truong D, Fernandez H, Comella C, Brodsky M, Jankovic J, Marx M, Grafe S

• Efficacy and safety of repeated incobotulinumtoxin A injections in subjects with cervical dystonia previously naive to botulinum toxin treatment.
  

  Fernandez H, Comella C, Brodsky M, Evidente VG, Jankovic J, Truong D, Marx M, Grafe S

• Intermediate CAG repeats: Analysis of the cooperative Huntington's observational research trial.
  

  Ha AD, Davidson A, Jankovic J

• Essential tremor quantification during activities of daily living.
  

  Heldman D, Filipkowski D, Jankovic J, Vaillancourt D, Prodoehl J, Elble R, Giuffrida J

• Cervical dystonia patient registry for observation of BOTOX® efficacy (CD PROBE): Interim results of physician-reported outcomes.
  

  Jankovic J, Charles P, Adler CH, Stacy M, Comella C, Boo LM, Brin M, Papapetropoulos S

• Double-blind, placebo-controlled fixed-dose trial of IPX066, a novel carbidopa-levodopa (CD-LD) extended-release formulation, in early Parkinson's disease (APEX-PD).
  

  Pahwa R, Hauser R, Jankovic J, Nausieda P, Ellenbough A, Hsu A, Gupta S

• AMPK-mediated neuroprotection on cellular models of Parkinson's disease.
  

  Pan T, Li X, Zhu J, Le W, Jankovic J

• Cervical dystonia patient registry for observation of BOTOX® efficacy (CD PROBE): Interim results of patient-reported outcomes.
  

  Stacy M, Charles P, Adler CH, Comella C, Jankovic J, Boo LM, Brin M, Varon S, Papapetropoulos S

• Postural instability and gait difficulty scores from the MDS-UPDRS.
  

  Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Tilley BC

• Psychosocial profiles of psychogenic movement disorder patients with non-epileptic seizures and other abnormal motor manifestations.
  

  Strutt AM, Scott BM, Ferrara JM, York MK, Jankovic J

• Diffusion tensor tractography of the internal capsule in depressed and anxious Parkinson's disease patients.
  

  York M, Yallampalli R, Gallander K, Strutt A, Chu Z, Karmonik C, Lai E, Jankovic J, Grossman R, Wilde E

AD/PD
10th International Congress on Alzheimer's and Parkinson's Diseases in Barcelona, Spain (March 9-13, 2011)

• Diffusion tensor tractography of the internal capsule differentiates stages of cognitive impairment in Parkinson's disease.
  

  York M, Yallampalli R, Gallander K, Strutt A, Chu Z, Karmonik C, Lai EC, Jankovic J, Grossman R, Wilde EA

Movement Disorder Society (MDS)
14th International Congress of Parkinson's Disease and Movement Disorders in Buenos Aires, Argentina (June 13-17, 2010)

• Longitudinal analysis of intermediate CAGn repeat length expansion in the prospective Huntington's disease at-risk observational study (PHAROS).
  

  Biglan KM, Jankovic J, Eberly S, Kayson E, Oakes D, Young AB, Shoulson I, HSG PHAROS Investigators

• CD-PROBE (cervical dystonia patient registry for observation of BOTOX® efficacy) — preliminary safety data.
  

  Charles D, Adler C, Comella C, Jankovic J, Stacy M, Kurth M, Brin MF, Boo LM

• Validation of a cervical dystonia questionnaire (CDQ).
  

  Davidson AL, Hunter C, Jankovic J

• Prospective 5-year natural history study of probable multiple system atrophy (MSA) in 175 North American subjects.
  

  Gilman S, Low P, May S, Tanner C, Stern M, Sandroni P, Reich S, Marshall F, Novak P, Jankovic J, Wooten GF, Racette B, Sletten D, Shults C

• Predictors of initial adverse events in subjects receiving intermittent apomorphine injections.
  

  Giovanni M, Hunter C, Ferrara J, Ondo WG

• Safety and efficacy of repeated NT 201 (botulinum neurotoxin type A free from complexing proteins) injections of patients with blepharospasm.
  

  Grafe S, Hanschmann A, Jankovic J, Comella C

• Validation of a motor screen for undiagnosed parkinsonism: The Baylor Functional Assessment Screen (BFAS).
  

  Hunter CB, York MK, Jankovic J

• CD-PROBE (cervical dystonia patient registry for observation of BOTOX® efficacy) — CD impact on quality of life (QOL) and patient reported outcomes (PRO).
  

  Kurth M, Adler C, Comella C, Charles D, Jankovic J, Stacy M, Brin MF, Boo LM

• Neuroprotection of pramipexole in UPS impairment induced animal model of Parkinson's disease.
  

  Li C, Xie W, Jankovic J, Le W

• Use of an interactive voice response system by patients with blepharospasm receiving repeated injections of NT 201 (botulinum neurotoxin type A free from complexing proteins).
  

  Marx M, Grafe S, Jankovic J, Comella C

• Assessing patients' access to tetrabenazine (xenazine) after FDA approval.
  

  Palao AM, Mostile G, Hunter CB, Jankovic J

• Curcumin accelerates the clearance of mutant alpha-synuclein and injured mitochondria via autophagy induction.
  

  Pan T, Wu Y, Le W, Jankovic J

• SETTLE study design: A 24-week, double-blind, placebo-controlled study of the efficacy and safety of safinamide as add-on therapy to levodopa in patients with Parkinson's diseases.
  

  Schapira AHV, Fox S, Hauser R, Jankovic J, Kulisevsky J, Pahwa R, Poewe W, von Raison F, Kenney C, Musch B

• Neuropsychological assessment of monolingual Spanish speaking Parkinson's disease patients in the United States pre and post STN-DBS.
  

  Strutt AM, Scott BM, Yaltho T, Simpson R, Jankovic J, York MK

• Open-label extension trial assessing the effects of long-term treatment with rotigotine in subjects with early-stage, idiopathic Parkinson's disease: Results from up to 7 years.
  

  Watts RL, Boroojerdi B, Jankovic J, on behalf of the SP702 Study Group

• Retrospective study of the therapeutic effect of deep brain stimulation in multiple system atrophy.
  

  Wu Y, Almaguer MA, Atassi F, Lai EC, Jankovic J, Ondo WG

• Orthostatic tremor: A review of 40 cases.
  

  Yaltho TC, Jankovic J, Ondo WG

American Academy of Neurology (AAN)
62nd Annual Meeting in Toronto, Canada (April 10-17, 2010)

• Upper face chorea in Huntington disease.
  

  Fekete R, Jankovic J

• Effect of tetrabenazine (TBZ) on motor function in patients with Huntington disease (HD).
  

  Ferrara J, Mostile G, Hunter C, Adam O, Jankovic J

• CD-PROBE (Cervical Dystonia Patient Registry for Observation of BOTOX® Efficacy) — A multicenter, observational study of onabotulinumtoxin A injections in cervical dystonia (CD) patients — Interim patient reported outcome data.
  

  Jankovic J, Adler C, Charles D, Comella C, Stacy M, Kurth M, Brin M, Misell L, Boo L

• CD-PROBE (Cervical Dystonia Patient Registry for Observation of BOTOX® Efficacy) — A multicenter, observational study of repeated onabotulinumtoxin A injections in cervical dystonia (CD) patients — Preliminary baseline data.
  

  Jankovic J, Adler C, Charles D, Comella C, Stacy M, Kurth M, Brin M, Misell L, Boo L

• Clinical correlates of eye movements in Huntington disease.
  

  Jeter C, Hood A, Palao A, Patel S, Jankovic J, Sereno A

• Ubiquitin proteasome system impairment mouse model of Parkinson's disease.
  

  Li X, Li C, Xie W, Jankovic J, Le W

• HIF-1α-mediated neuroprotection on MPP+-induced apoptosis in SH-SY5Y cells.
  

  Pan T, Wu Y, Xie W, Le W, Jankovic J

• The natural progression of clinical symptoms in Parkinson's disease may not be faster in the earlier stages: Results from the ADAGIO delayed-start study.
  

  Rascol O, for the ADAGIO investigators

• Open-label extension trial assessing the effects of long-term treatment with rotigotine in subjects with early-stage, idiopathic Parkinson's disease: Results from up to seven years.
  

  Watts R, Boroojerdi B, Jankovic J, on behalf of the SP702 Study Group

• Asian over representation among patients with hemifacial spasm compared to cranial dystonia.
  

  Wu Y, Davidson A, Huang M, Pan T, Jankovic J

• A novel set shifting fMRI task identifies differences in brain activation in Parkinson's disease and healthy controls.
  

  York M, Karmonik C, Burton P, Richards D, Kakkar E, Grossman R, Jankovic J

World Federation of Neurology (WFN)
XVIII World Congress on Parkinson's Disease and Related Disorders in Miami Beach, Florida (Dec. 13-16, 2009)

• Rasagiline provides symptomatic beneflt in early Parkinson's disease (PD).
  

  Jankovic J, ADAGIO Investigators

• Multicenter, randomized, double-blind, sham surgery-controlled study of intraputaminal AAV2-neurturin (CERE-120) for advanced Parkinson's disease (PD).
  

  Marks Jr W, Bartus R, Siffert J, Starr P, Ostrem J, Stacy M, Boulis N, Vitek J, Verhagen L, Watts R, Jankovic J, Tagliati M, Stern M, Nutt J, Kordower J, Lozano A, Kieburtz K, Davis C, Bloom F, Olanow CW

• Treatment of dysautonomia associated with Parkinson's disease.
  

  Mostile G, Jankovic J

Baylor College of Medicine
Current Neurology 2009 in Houston, Texas (Oct. 31 - Nov. 1, 2009)

• Influence of levodopa and psychotropic medication on emotional and physical symptoms of depression before and following STN-DBS for the treatment of Parkinson's disease.
  

  Gallander KM, Strutt AM, Simpson R, Jankovic J, York MK

• Alternating fluency performance following bilateral STN DBS for the treatment of Parkinson's disease.
  

  Marshall DF, Williams AE, Strutt AM, Jankovic J, York MK

Movement Disorder Society (MDS)
13th International Congress of Parkinson's Disease and Movement Disorders in Paris, France (June 7-11, 2009)

• Long-term deep brain stimulation for essential tremor: 12- year clinicopathologic follow up and literature review.
  

  DiLorenzo DJ, Jankovic J, Simpson RK, Takei H, Powell SZ

• Double-blind, randomized, placebo-controlled, cross-over trial of pregabalin in essential tremor.
  

  Ferrara FM, Kenney C, Davidson AL, Shinawi L, Kissel AM, Jankovic J

• Impact of STN-DBS on health-related quality of life in patients with Parkinson's disease.
  

  Ferrara JM, Diamond A, Davidson A , Almaguer M, Jankovic J

• Tourette syndrome in adults.
  

  Gelineau-Kattner RN, Jankovic J, Davidson AL

• Efficacy and safety of NT 201 (botulinum neurotoxin type A free from complexing proteins) in treatment-naive cervical dystonia patients.
  

  Grafe S, Comella C, Jankovic J, Truong D, Hanschmann A

• Efficacy and safety of NT 201, botulinum neurotoxin type A free from complexing proteins) in pre-treated cervical dystonia patients.
  

  Grafe S, Comella C, Jankovic J, Truong D, Hanschmann A

• A randomized, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome.
  

  Jankovic J, Jimenez-Shahed J, Brown LW

• Transcription factor PITX3 in Parkinson's disease.
  

  Le W, Nguyen D, Lin W, Rawal P, Ding Y, Xie W, Deng H, Jankovic J

• Correlation between Kinesia system assessments and clinical TETRAS scores in patients with essential tremor.
  

  Mostile G, Giuffrida JP, A dam OR, Davidson A, Jankovic J

• 17-AAG protects against rotenone-induced apoptosis in SHSY5Y cells via HSP70 induction.
  

  Pan T, Xie W, Jankovic J, Le W

• Resveratrol, a polyphenol found in red wine, protects against rotenone-induced apoptosis through autophagy induction.
  

  Pan T, Xie W, Le W, Jankovic J

• The course of depressive symptoms in early Parkinson's disease.
  

  Ravina B, Elm J, Camicioli R, Como P, Marsh L, Jankovic J, Weintraub D

• Mood differences between women diagnosed with psychogenic movement disorders and psychogenic seizures.
  

  Strutt AM, Ferrara J, Hill S, York MK, Uber-Zak L, Fogel T, Jankovic J

American Academy of Neurology (AAN)
61st Annual Meeting in Seattle, Washington (April 25 - May 2, 2009)

• The written and oral administration of the Symbol Digit Modality Test in Huntington disease.
  

  Adam O, Halton S, Mostile G, Jankovic J

• Efficacy and safety of NT 201 (neurotoxin free from complexing proteins) in cervical dystonia.
  

  Comella C, Jankovic J, Truong D, Hanschmann A, Grafe S

• Efficacy and safety of NT 201 (botulinum neurotoxin free from complexing proteins) in blepharospasm.
  

  Jankovic J, Comella C, Hanschmann A, Grafe S

• Rapamycin protects against rotenone-induced apoptosis through autophagy induction in SH-SY5Y cells.
  

  Pan T, Xie W, Rawal P, Jankovic J, Le W

• A controlled study of the long-term cognitive outcome of bilateral subthalamic nucleus deep brain stimulation.
  

  Williams A, Arzola GM, Strutt AM, Simpson R, Jankovic J, York MK

6th International Congress on Mental Dysfunctions and Other Non-Motor Features in Parkinson's Disease and Related Disorders
Dresden, Germany (Oct. 16-19, 2008)

• Voxel-based diffusion tensor imaging and diffusion tensor tractography for the evaluation of cognitive functioning in Parkinson's disease.
  

  York M, Karmonik C, Wilde E, Kakkar E, Yallampalli R, Strutt A, Jankovic J, Grossman R

American Neurological Association (ANA)
133rd Annual Meeting in Salt Lake City, Utah (Sept. 21-24, 2008)

• Progressive DA neuron degeneration induced by targeting administration of proteasome inhibitor in SN.
  

  Xie W, Zhu W, Pan T, Jankovic J, Le W

Movement Disorder Society (MDS)
12th International Congress of Parkinson's Disease and Movement Disorders in Chicago, Illinois (June 22-26, 2008)

• Unusual motor-phonic tic mimicking essential palatal myoclonus (EPM).
  

  Adam OR, Jankovic J

• Correlation between clinical rating of parkinsonian and essential tremor and quantitative assessments.
  

  Aguilar LG, Giuffrida JP, Heldman DD, Jankovic J

• The essential tremor rating assessment scale (TETRAS).
  

  Elble R, Comella C, Fahn S, Hallett M, Jankovic J, Juncos J, Louis E, Lyons K, Ondo WG, Pahwa R, Sethi K, Stern M, Tanner C, Tarsy D, Tintner R, Watts R, Tremor Research Group

• Spinocerebellar Ataxia 8: Variable phenotype and unique pathogenesis.
  

  Gupta A, Jankovic J

• Evaluation of a Parkinson's disease screening questionnaire for use in a community-based setting.
  

  Hunter CB, Aguilar LG, Nashatizadeh MM, Lay LF, Jankovic J

• The role of dopaminergic medication doses in impulse control disorders (ICD) in Parkinson's disease (PD).
  

  Jimenez-Shahed J, Baker K, Davidson A, Jankovic J

• Topiramate in treatment of Tourette's syndrome (TS).
  

  Kuo SH, Jimenez-Shahed J

• Expanded study of NURR1 gene expression in patients with Parkinson's disease.
  

  Le WD, Pan T, Xie W, Huang M, Xu P, Zhu W, Zhang X, Deng H, Jankovic J

• Deep brain stimulation of the subthalamic nucleus for peripherally-induced parkinsonism.
  

  Nashatizadeh MM, Jankovic J

• A randomized, double-blind, placebo-controlled study of atomoxetine for freezing of gait in Parkinson's disease.
  

  Nashatizadeh MM, Jimenez JE, Davidson AL, Jankovic J

• Tolerability and efficacy of switching from swallowed selegiline to zydis selegiline (Zelapar®) in patients with Parkinson's disease.
  

  Ondo WG, Hunter CB, Davidson A, Isaacson SH, Silver DE, Stewart RM, Tetrud JW

• Rapamycin rescues lactacystin-induced dopaminergic neuron injury in vivo.
  

  Pan T, Xie W, Jankovic J, Le WD

• Neuropsychological functioning of Parkinson's disease patients two years post subthalamic nucleus deep brain stimulation surgery.
  

  Strutt AM, Jankovic J, York MK

• Experience with MRI safety and DBS: Data from the National Parkinson Foundation Centers of Excellence.
  

  Tagliati M, Jankovic J, Koss AM, Pagan F, Okun MS, National Parkinson Foundation DBS Working Group

American Academy of Neurology (AAN)
60th Annual Meeting in Chicago, Illinois (April 12-19, 2008)

• Volume and nature of patient telephone calls in a large movement disorders center.
  

  Adam OR, Aguilar Tabora LG, Ferrara J, Nashatizadeh M, Jankovic J

• Characteristics of archimedean spiral drawing in patients with psychogenic tremor.
  

  Aguilar Tabora LG, Davidson A, Jankovic J, Ondo WG

• Morbidity associated with psychogenic movement disorders in children.
  

  Ferrara JM, Jankovic J

• Phenomenology of psychogenic movement disorders in children.
  

  Ferrara JM, Jankovic J

• New version of the UPDRS (MDS-UPDRS): Factor analysis.
  

  Goetz CG, Tilley BC, Shaftman SR, Fahn S, Martinez-Martin P, Poewe W, et al.

• Craving for sweets and other compulsive behaviors in patients with Parkinson's disease.
  

  Jimenez-Shahed J, Calhoun K, Davidson A, Jankovic J

• Acamprosate improves impulse control disorders in Parkinson's disease.
  

  Jimenez-Shahed J, Hunter CB, Jankovic J

• Treatment of freezing of gait in Parkinson's disease with deep brain stimulation of the pedunculopontine nucleus.
  

  Nashatizadeh M, Jankovic J

• Role of deferoxamine and autophagy induction in rotenone-induced apoptosis.
  

  Pan T, Li X, Xie W, Jankovic J, Le WD

• Changes in emotional versus physical symptoms of depression following sub-thalamic nucleus deep brain stimulation for Parkinson's disease.
  

  Strutt AM, York MK, Jankovic J

• Hemidystonia-hemiatrophy syndrome.
  

  Wijemanne S, Jankovic J

Movement Disorder Society (MDS)
11th International Congress of Parkinson's Disease and Movement Disorders in Istanbul, Turkey (June 3-7, 2007)

• Rotigotine transdermal patch as a treatment of nocturnal symptoms in patients with idiopathic Parkinson's disease.
  

  Chaudhuri KR, Jankovic J, Trenkwalder C, Boroojerdi B

• Clinimetric testing of the new UPDRS (MDS-UPDRS) vs. original version.
  

  Goetz CG, Tilley BC, Shaftman S, Stebbins GT, Fahn S, Martinez-Martin P, et al.

• Clinical features of movement disorders in hemochromatosis.
  

  Hall DA, Ringel S, Howard K, Jankovic J

• Deep brain stimulation for tardive dyskinesia and akathisia.
  

  Kenney C, Barbano R, Sheffield KJ, Jankovic J

• Health related quality of life in essential tremor patients undergoing deep brain stimulation.
  

  Kenney C, Diamond AL, Davidson A, Shinawi LM, Jankovic J

• Health related quality of life in Parkinson's disease patients undergoing deep brain stimulation.
  

  Kenney C, Diamond AL, Davidson A, Shinawi LM, Jankovic J

• Switch from an oral dopamine agonist to rotigotine transdermal patch in Parkinson's disease.
  

  LeWitt PA, Patton JM, MacMahon DG, Jankovic J

• Motor and behavioral outcomes after bilateral GPi deep brain stimulation for severe Tourette syndrome.
  

  Shahed J, Poysky J, Kenney C, Simpson R, Jankovic J

• Weight change in parkinson and alzheimer patients taking atypical antipsychotic drugs.
  

  Sitburana O, Rountree S, Vuong KD, Ondo W

• Shoulder pain in Parkinson's disease.
  

  Stamey W, Jankovic J

• The other Babinski sign in hemifacial spasm.
  

  Stamey W, Jankovic J

• The specificity and sensitivity of "applause sign" in differentiating PSP and other parkinsonian syndromes.
  

  Wu J, Sitburana O, Jankovic J

• Brain permeable iron chelators M-30 and AK-28 rescue degenerated nigral dopamine neurons in animal model of PD.
  

  Zhu W, Pan T, Xie W, Jankovic J, Zheng H, Youdim M, Le W

American Academy of Neurology (AAN)
59th Annual Meeting in Boston, Massachusetts (April 28 - May 5, 2007)

• Malignant Tourette syndrome.
  

  Cheung MC, Shahed J, Jankovic J

• Three parkin mutations in a family with Parkinson's disease.
  

  Deng H, Le W, Shahed J, Jankovic J

• Autopsy-proven Huntington disease with 29 trinucleotide repeats.
  [Previously Presented]
  

  Kenney C, Powell S, Jankovic J

• Autophagy induction and its neuroprotection on neurotoxin-induced cell injury relevant to Parkinson's disease.
  

  Pan T, Li X, Zhu W, Xie W, Jankovic J, Le W

• Motor overflow, contralateral dystonia and mirror movements in focal hand dystonia.
  

  Sitburana O, Wu LJC, Sheffield KJ, Davidson A, Jankovic J

• Head injury with amnesia and risk of multiple system atrophy (MSA).
  

  Tanner C, Kukrull W, Shults C, Comyns K, Bhudhikanok G, May S, Goldman S, Meng C, Gilman S, Chade A, Kasten M, Colcher A, Huang N, Jankovic J, Low P, Marshall F, Novak P, Ondo W, Racette B, Reich S, Sandroni P, Stern M, Wooten GF

• Novel brain permeable iron chelators prevent lactacystin induced ubiquitn-proteasome inhibition and degeneration of nigrostrialtal dopamine neurons.
  

  Zhu W, Pan T, Xie W, Xu P, Zheng H, Fridkin M, Jankovic J, Youdim MBH, Le W

• Proteasome inhibition in substantial nigra induces sustained dopamine cells degeneration.
  

  Zhu W, Pan T, Zhang X, Xie W, Jankovic J, Le W

8th International Conference on Alzheimer's and Parkinson's Diseases (ADPD)
Salzburg, Austria (March 14-18, 2007)

• Comparison of neuroprotective and neurorescue capabilities of rasagiline and selegiline, against lactacystin induced nigrostriatal degeneration.
  

  Zhu W, Pan T, Xie W, Xu P, Jankovic J, Youdim MBH, Le W

Movement Disorder Society (MDS)
10th International Congress of Parkinson's Disease and Movement Disorders in Kyoto, Japan (Oct. 30 - Nov. 2, 2006)

• Examination of LRRK2 I2012T, G2019S, and I2020T mutations in patients with essential tremor.
  

  Deng H, Le W, Davidson AL, Xie W, Jankovic J

• The effects of subthalamic nucleus deep brain stimulation on parkinsonian tremor.
  

  Diamond A, Shahed J, Jankovic J

• Deep brain stimulation of the subthalamic nucleus on Parkinson's disease: Effects on quality of life.
  

  Diamond AL, Vuong KD, Jankovic J

• Comparing knowledge and attitudes towards genetic testing in Parkinson's disease in an American and Asian population.
  

  Hunter CB, Tan EK, Lee J, Shinawi LM, Fook-Chong S, Jankovic J

• Hyperhidrosis due to thalamic deep brain stimulation in a patient with essential tremor.
  

  Kenney C, Diamond AL, Jankovic J

• Clinical features that distinguish psychogenic and essential tremor.
  

  Kenney C, Diamond AL, Mejia N, Hunter CB, Jankovic J

• Short-term effects of tetrabenazine on chorea associated with Huntington disease.
  [Previously Presented]
  

  Kenney C, Hunter CB, Davidson A, Jankovic J

• Autopsy-proven Huntington disease with 29 trinucleotide repeats.
  

  Kenney C, Powell S, Jankovic J

• Enhancement of autophagy and neuroprotection by rapamycin in lactacystin-induced injury of dopaminergic neurons.
  

  Pan T, Kondo S, Zhu W, Xie W, Jankovic J, Le W

• Executive dysfunction and comorbid conditions in Tourette syndrome.
  

  Poysky J, Khan H, Krull K, Jankovic J

• Craving sweets in Parkinson's disease.
  

  Shahed J, Davidson A, Jankovic J

• GPI deep brain stimulation for Tourette syndrome improves tics and psychiatric co-morbidities.
  

  Shahed J, Poysky J, Kenney C, Simpson Jr RK, Jankovic J

• Overflow, contralateral and mirror hand dystonia.
  

  Sitburana O, Jankovic J

• Hemiparkinsonism-hemiatrophy syndrome.
  

  Wijemanne S, Jankovic J

• Different faces of hemifacial spasm: Etiological classification.
  

  Wu LJC, Jankovic J

• Runner's dystonia.
  

  Wu LJC, Jankovic J

• Relationship of MRI localization and cognition in DBS.
  

  York MK, Wilde E, Simpson Jr RK, Jankovic J

American Neurological Association (ANA)
131st Annual Meeting in Chicago, Illinois (Oct. 8-11, 2006)

• Examination of LRRK2 I2012T, G2019S, and I2020T mutations in patients with essential tremor.
  

  Deng H, Le W, Guo Y, Hunter CB, Xie W, Huang M, Jankovic J

• A Mexican pedigree with Parkinson's disease, essential tremor and bell's palsy associated with parkin but not HS1BP3 gene mutation.
  

  Deng H, Le W, Hunter CB, Xie W, Mejia N, Jankovic J

• Genetic analysis of the SLITRK1 gene in caucasian patients with Tourette syndrome.
  

  Deng H, Le W, Xie W, Jankovic J

• Deep brain stimulation of the subthalamic nucleus on Parkinson's disease: Effects on quality of life.
  [Previously Presented]
  

  Diamond AL, Vuong KD, Jankovic J

• Medications associated with the onset of tardive dyskinesia.
  

  Hunter CB, Kenney K, Mejia N, Davidson A, Jankovic J

• Short-term effects of tetrabenazine on chorea associated with Huntington disease.
  

  Kenney C, Hunter CB, Davidson A, Jankovic J

American Academy of Neurology (AAN)
58th Annual Meeting in San Diego, California (April 1-8, 2006)

• Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders.
  

  Kenney C, Simpson Jr RK, Hunter CB, Ondo WG, Almaguer M, Davidson A, Jankovic J

• Long term safety of deep brain stimulation for the treatment of Parkinson's disease.
  

  Kenney CJ, Vuong K, Hunter C, Almaguer M, Jankovic J

• Nurrl deficiency predisposes to apoptosis induced by lactacystin in SH-SY5Y cells in vitro.
  

  Pan T, Xie W, Deng H, Zhao H, Jankovic J

• Bilateral GPI deep brain stimulation for Tourette syndrome.
  

  Shahed J, Poysky J, Kenney C, Simpson Jr RK, Jankovic J

• Frontostriatal cognitive functioning 6 months following bilateral subthalamic nucleus deep brain stimulation.
  

  York MK, Jankovic J, Lai EC, Dulay M

International Neuropsychological Society (INS)
34th Annual Meeting in Boston, Massachusetts (Feb. 1-4, 2006)

• Neuropsychological outcome after bilateral deep brain stimulation surgery for advanced Parkinson's disease: Base rates adjusted for practice effects, test unreliability, and natural disease progression.
  

  Dulay MF, York MK, Jankovic J, Simpson Jr RK

American Neurological Association (ANA)
130th Annual Meeting in San Diego, California (Sept. 25-28, 2005)

• Botulinum toxin type B Observational Study (BOS).
  

  Jankovic J, Hunter CB, the BOS Study Group

American Academy of Neurology (AAN)
57th Annual Meeting in Miami Beach, Florida (April 9-16, 2005)

• Genetic analysis of G309D and W4370PA mutations of PINK1 in Parkinson's disease.
  

  Deng H, Le W, Zhang X, Pan T, Jankovic J

• New version of the UPDRS: Development methods and working document for field testing.
  

  Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins G, et al.

• A variant in the HS1-BP3 gene is associated with familial essential tremor.
  

  Higgins JJ, Lombardi RQ, Pucilowska J, Jankovic J, Tan EK, Rooney JP

• Convergence spasm and other psychogenic eye movement disorders.
  

  Mejia NI, Jankovic J

• Tics associated with other disorders.
  

  Mejia NI, Jankovic J

• HSP70 inducer VPA inhibits rotenone-induced apoptosis in SH-SY5Y cells.
  

  Pan T, Xie W, Jankovic J, Le W

• Characteristics of Parkinson's disease in patients with childhood-onset essential tremor.
  [Previously Presented]
  

  Shahed J, Diamond AL, Vuong KD, Jankovic J

• Botulinum toxin treatment for oromandibular dystonia and bruxism in patients with Tourette syndrome.
  

  Silay YS, Jankovic J

Movement Disorder Society (MDS)
9th International Congress of Parkinson's Disease and Movement Disorders in New Orleans, Louisiana (March 5-8, 2005)

• Gait and balance assessment in parkinsonian disorders.
  

  Azher SN, Vuong KD, Shahed J, Diamond AL, Jankovic J

• Small interfering RNA (SiRNA) targeting the PINK1 induces apoptosisin human SH-SY5Y cells.
  

  Deng H, Jankovic J, Pan T, Xie W, Le W

• Reduced NURR1 gene expression affects expression of dopaminergic phenotypic markers and Parkinson's disease-related genes.
  

  Deng H, Jankovic J, Xie W, Pan T, Le W

• Globus pallidus deep brain stimulation in dystonia.
  

  Diamond AL, Shahed J, Azher SN, Vuong KD, Jankovic J

• Relationship among psychiatric, motor and cognitive functioning in non-demented individuals with Parkinson's disease.
  

  Dulay MF, Levin HS, Jankovic J, Lai EC, York MK

• Tetrabenazine: Does prior history of depression preclude this drug as a treatment option?
  

  Hunter C, Vuong KD, Mejia N, Jankovic J

• Botulinum toxin type B Observational Study (BOS).
  

  Jankovic J, Hunter C, Atassi MZ, Dolimbek BZ, Dolimbek GS, and BOS Research Group

• Prevalence of cervical dystonia and spasmodic torticollis in the United States.
  

  Jankovic J, Tsui J, Bergeron C

• Medications associated with the onset of tardive dyskinesia.
  

  Mejia N, Vuong KD, Hunter C, Jankovic J

• A pilot study of the clinical efficacy and safety of memantine for Huntington's disease.
  

  Mejia NI, Hunter C, Flores K, Ondo WG

• Predictors of battery life for the Activa® Soletra 7426 neurostimulator.
  

  Ondo WG, Meilak C, Vuong KD, Jankovic J

• Subthalamic deep brain stimulation in patients with a previous pallidotomy.
  

  Ondo WG, Silay Y, Almaguer M, Jankovic J

• Characteristics of Parkinson's disease in patients with childhood-onset essential tremor.
  

  Shahed J, Diamond AL, Vuong KD, Jankovic J

• Parkinsonism associated with adalimumab in a patient with rheumatoid arthritis.
  

  Tintner R, Silay YS, Sessoms S, Jankovic J

American Neurological Association (ANA)
129th Annual Meeting in Toronto, Canada (Oct. 4-5, 2004)

• Botulinum toxin serotype A compared to B in cervical dystonia: Randomized, double-blind, parallel study.
  

  Comella CL, Jankovic J, Leurgans S, Fan W, Chmura T, the Dystonia Study Group

• The safety of deep brain stimulation in patients with Parkinson's disease, essential tremor, and other movement disorders.
  

  Silay Y, Jankovic J, Vuong KD, Almageur M, Ondo WG, Tintner R, Simpson Jr RK

Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders
18th Annual Symposium in Toronto, Canada (Oct. 3, 2004)

• Safety and efficacy of tetrabenazine in the treatment of Huntington's disease and other choreas.
  

  Jankovic J, Hunter CB, Vuong KD

• The Tremor Rating Scale (TRS).
  

  Tintner R for the Tremor Research Group

Movement Disorder Society (MDS)
8th International Congress of Parkinson's Disease and Movement Disorders in Rome, Italy (June 13-17, 2004)

• Tetrabenazine, a monoamine depleter, effective in the treatment of Tourette syndrome.
  

  Hunter C, Vuong KD, Mejia N, Jankovic J

• Tetrabenazine: Effective treatment for tardive dyskinesia.
  

  Jankovic J, Hunter C, Mejia N, Vuong KD

• A multicenter, double-blind, placebo-controlled trial of topiramate in essential tremor.
  

  Jankovic J, Ondo WG, Stacy MA, Elble RJ, Pahwa R, Connor GS, Hulihan FJ, Schwarzman L, Wu SC

• Nurr1 gene targeting therapy for Parkinson disease.
  

  Le W, Jiang Q, Xie W, Hintermann S, Jankovic J

• The pharmacological and biological effects of pramipexole on dopamine neuron associated genes: DAT, VMAT-2, and Nurr1.
  

  Pan T, Xie W, Jankovic J, Le W

• Young-onset versus late-onset Parkinson's disease: Clinical features and disease progression.
  

  Silver GA, Vuong KD, Jankovic J

• Long-term prognosis of psychogenic movement disorders.
  

  Thomas M, Banuelos P, Vuong KD, Jankovic J

• Psychogenic dystonia: Clinical characteristics and long-term progression.
  

  Thomas M, Vuong KD, Jankovic J

• A double-blind, randomized, parallel group design comparison of botulinum toxin, type A (Botox) and botulinum toxin, type B (Myobloc) on systemic and ocular autonomic symptoms and physiology in patients with cervical dystonia.
  

  Tintner R, Gross RL, Winzer UF, Smalky KA, Jankovic J

• Safety and efficacy of tetrabenazine in childhood hyperkinetic movement disorders.
  

  Vuong KD, Hunter C, Mejia N, Jankovic J

• Is depression a predictor of outcome after bilateral subthalamic deep brain stimulation in patients with Parkinson's disease?
  

  York MK, Silay YS, Chaytor N, Simpson Jr RK, Jankovic J

American Academy of Neurology (AAN)
56th Annual Meeting in San Francisco, California (April 24 - May 1, 2004)

• Camptocormia: Pathogenesis, classification and response to therapy.
  

  Azher S, Jankovic J

• Interim results of an observational study of neutralizing antibody formation with the current preparation of botulinum toxin type A treatment for cervical dystonia.
  

  Comella CL, Jankovic J, Daggett S, Mordaunt J, Brin MF

• Haplotype analysis at the ETM2 locus in American and Singaporean populations with familial essential tremor.
  

  Higgins JJ, Lombardi RQ, Tan EK, Jankovic J, Pucilowska J, Rooney JP

• Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders.
  

  Hunter CB, Vuong KD, Jankovic J

• Essential tremor in children.
  

  Jankovic J, Madisetty J, Vuong KD

• Psychogenic tremor: Long-term outcome.
  

  Jankovic J, Vuong KD, Thomas M

• Effects of ropinirole on progression of parkinsonism in Nurr1-deficient mice and its underlying mechanisms.
  

  Jiang C, Pan T, Jankovic J, Le W

• Dopaminergic properties and anti-parkinsonian effects of IPX750 in rodent models of Parkinson's disease.
  

  Jiang C, Wan X, Jankovic J, Christian S, Sundsmo J, Le W

• The pharmacological and biological effects of pramipexole on dopamine transporter.
  

  Pan T, Jankovic J, Le W

• Decreased Nurr1 mRNA in peripheral blood lymphocytes in Parkinson's disease.
  

  Pan T, Xie W, Jankovic J, Le W

• The efficacy and safety of fluphenazine in patients with Tourette syndrome.
  

  Silay YS, Vuong KD, Jankovic J

• A double-blind, randomized, parallel group design comparison of botulinum toxin, type A (Botox®) and botulinum toxin, type B (Myobloc™) on autonomic symptoms and physiology in patients with cervical dystonia.
  

  Tintner R, Winzer UF, Smalky KA, Jankovic J

American Society for Experimental NeuroTherapeutics (ASENT)
6th Annual Meeting in Bethesda, Maryland (March 11-13, 2004)

• Tetrabenazine in the treatment of chorea.
  

  Jankovic J, Hunter CB, Vuong KD

International Neuropsychological Society (INS)
32nd Annual Meeting in Baltimore, Maryland (Feb. 4-7, 2004)

• Information processing speed influences the component processes of verbal working memory in Parkinson's disease patients.
  

  York MK, Levin HS, Soety EM, Lai EC, Jankovic J, Grossman RG

American Academy of Neurology (AAN)
55th Annual Meeting in Honolulu, Hawaii (March 29 - April 5, 2003)

• Haplotype analysis of unrelated individuals with familial essential tremor.
  

  Higgins JJ, Jankovic J, Lombardi RQ, Pucilowska J, Tan EK, Ashizawa T, Ruszczyk MU

• Comparison of postoperative improvement of staged bilateral subthalamic stimulation in patients with advanced Parkinson's disease.
  

  Kuniyoshi S, Tintner R, Ondo W, Simpson R, Jankovic J

• Apolipoprotein E controls risk and age at onset of Parkinson disease.
  

  Li Y-J, Martin ER, Scott WK, Haines JL, Nance MA, Hubble JP, Hiner BC, Jankovic J, Goetz CG, Small GW, Gibson RA, Middleton LT, Vance JM

• Glutathione S-Transferase, Omega-1 (GSTO1) modifies age at onset of Alzheimer disease and Parkinson disease.
  

  Li Y-J, Oliveria AS, Hauser MA, Hauser ER, Scott WK, Stenger JE, Hubble JP, Koller WC, Hiner BC, Jankovic J, Allen Jr FH, Roses AD, Saunders AM, Schmechel DA, Small GW, Gullans SR, Gilbert JR, Vance JM, Pericak-Vance MA

• A double blind placebo controlled parallel trial of botulinum toxin B (Myobloc™) for the treatment of sialorrhea in parkinson disease.
  

  Ondo WG, Hunter CB, Moore W

• Long term treatment of restless legs syndrome with dopamine agonists.
  

  Ondo WG, Romanyshyn J, Vuong KD

• The epidemiology of myoclonus in the medical and surgical intensive care unit (ICU).
  

  Tintner R, Kuniyoshi SM, Gonzalez A, Jankovic J

• Specific mitochondrial haplogroups affect risk for late-onset Parkinson disease.
  

  Van der Walt JM, Nicodemus KK, Martin ER, Scott WK, Haines JL, McLaurin AC, Nance MA, Hubble JP, Koller WC, Padwa R, Stern MB, Hiner BC, Jankovic J, Goetz CG, Small GW, Mastaglia F, Gibson RA, Middleton LT, Pericak-Vance MA, Vance JM

Movement Disorder Society (MDS)
7th International Congress of Parkinson's Disease and Movement Disorders in Miami, Florida (Nov. 10-14, 2002)

• Treatment of hypophonia with collagen vocal fold augmentation in patients with parkinsonism.
  

  Hill AN, Jankovic J, Vuong KD, Donovan D

• Age-related tolerability of tetrabenazine.
  

  Hunter CB, Wang A, Vuong KD, Jankovic J

• Tetrabenazine in the treatment of Tourette syndrome.
  

  Hunter CB, Wang A, Vuong KD, Jankovic J

• Premonitory sensations in tics.
  

  Kwak CH, Jankovic J

• Reduced Nurr1 expression increases the susceptibility to dopaminergic toxins via nitric oxide.
  

  Le W, Imam SZ, Xie W, Ali S, Jankovic J

• Computerized posturography balance assessment of patients with bilateral vim deep brain stimulation.
  

  Ondo WG, Cohen H, Almaguer M, Jankovic J

• Evaluating factors that can influence spirography ratings in patients with essential tremor.
  

  Ondo WG, Wang A, Thomas M, Vuong KD

• Upregulation of Nurr1 gene expression by dopamine receptor agonist pramipexole in human neuroblastoma SHSY-5Y cells.
  

  Pan TH, Xu PY, Xie WJ, Hunter C, Jankovic J, Le WD

• Reliability of limits of stability measures in Parkinson's disease.
  

  Protas EJ, Thomas M, Cunha IT, Caroline KS, Wankadia S, Jankovic J

• Minocycline in Huntington's disease: A pilot study.
  

  Thomas M, Ashizawa T, Jankovic J

• Gait and Balance Scale (GABS): Validation and utilization.
  

  Thomas M, Jankovic J, Suteerawattanon M, Wankadia S, Caroline K, Protas E

• Experience with bilateral subthalamic nucleus (STN) stimulation for Parkinson's disease (PD).
  

  Tintner R, Almaguer M, Sanghera M, Simpson R, Ondo WG, Jankovic J

• Predictors of response to bilateral subthalamic nucleus stimulation for Parkinson's disease.
  

  Tintner R, Almaguer M, Vuong KD, Ondo WG, Jankovic J, Sanghera M

• Pleuropulmonary fibrosis after 11 years of pergolide treatment.
  

  Tintner R, Manian P, Gauthier P, Jankovic J

• The efficacy and safety of Dysport (botulinum type A toxin) in cervical dystonia: Results of the first US study.
  

  Truong DD, Duane DD, Jankovic J, Singer C, Comella CL, the US Dysport Dystonia Study Group

American Neurological Association (ANA)
127th Annual Meeting in New York, NY (Oct. 12-16, 2002)

• Dystonia in Friedreich's ataxia.
  

  Hou JG, Jankovic J

American Headache Society
44th Annual Scientific Meeting in Seattle, Washington (June 21-23, 2002)

• Botulinum toxin A (Botox) for chronic daily headache: A randomized placebo-controlled, parallel design study.
  

  Ondo WG, Vuong KD, Derman HS

Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins
International Conference in Hannover, Germany (June 8, 2002)

• Comparison of immunogenicity of old versus current Botox in cervical dystonia.
  

  Jankovic J, Ahsan J, Vuong KD

American Academy of Neurology (AAN)
53rd Annual Meeting in Philadelphia, Pennsylvania (May 5-11, 2001)

• The prevalence of restless legs syndrome in patients with Parkinson's disease.
  

  Atassi F, Vuong KD, Jankovic J, Ondo WG

• Exploring the relationship between Parkinson's disease and restless legs syndrome.
  

  Ondo WG, Vuong KD, Jankovic J

Movement Disorder Society (MDS)
6th International Congress of Parkinson's Disease and Movement Disorders in Barcelona, Spain (June 11-15, 2000)

• Olanzapine treatment for dopaminergic induced hallucinations.
  

  Ondo WG, Hunter C, Vuong KD, Jankovic J

• Daytime sleepiness in patients with Parkinson's disease.
  

  Ondo WG, Vuong KD, Atassi F, Khan H, Kwak C, Jankovic J

American Academy of Neurology (AAN)
52nd Annual Meeting in San Diego, California (April 29 - May 6, 2000)

• Unilateral thalamic deep brain stimulation for essential tremor and Parkinson's disease: Effects of stimulation on the non-target limb and rebound augmentation.
  

  Vuong KD, Ondo WnG, Almaguer M, Simpson RK, Jankovic J

American Academy of Neurology (AAN)
46th Annual Meeting in Washington, DC (May 1-7, 1994)

• Neuropsychological distinctions between cortico-basal ganglionic degeneration (CBGD) and Alzheimer's disease with extrapyramidal signs.
  

  Massman PJ, Kreiter KT, Jankovic J, Doody RS

International Neuropsychological Society (INS)
22nd Annual Meeting in Cincinnati, Ohio (Feb. 2-5, 1994)

• Neuropsychological differentiation of corticobasal degeneration from Alzheimer's disease.
  

  Massman PJ, Kreiter KT, Jankovic J, Doody RS

American Academy of Neurology (AAN)
43rd Annual Meeting in Boston, Massachusetts (April 21-27, 1991)

• The alien hand and related signs.
  

  Doody RS, Jankovic J